CytomX disclosed Phase 1 expansion data for its masked antibody‑drug conjugate Varseta‑M showing objective response rates of roughly 20–32% in late‑line metastatic colorectal cancer and progression‑free survival extensions of about 6.8–7.1 months. The company said it will discuss a monotherapy development path with the FDA and present more data at upcoming meetings. Separately, Astellas announced it is exiting a $1.6 billion research pact with CytomX after six years, removing a major partnership from the company’s portfolio. The two developments together affect CytomX’s clinical and commercial strategy: promising early efficacy creates regulatory pathways, while the loss of a biobucks partner raises questions about funding and downstream commercialization.